[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Shitaka
Yoshitsugu
Y
yoshitsugu@jp.astellas.com
Mitani
Yasuyuki
Y
Nagakura
Akira
A
Miyake
Akira
A
Matsuoka
Nobuya
N
D000409:Alanine / Q000031:analogs & derivatives; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D001381:Azepines; D015195:Drug Design; D004791:Enzyme Inhibitors; D005480:Flurbiprofen; D006801:Humans; D013654:Taurine / Q000031:analogs & derivatives
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D001381:Azepines; D004791:Enzyme Inhibitors; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D013654:Taurine; C505522:tarenflurbil; D005480:Flurbiprofen; C001355:tramiprosate; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human; D000409:Alanine